Clarity Pharmaceuticals Builds Toward US Prostate Imaging Launch

Phase III prostate imaging trials approach decisive readouts

Clarity Pharmaceuticals Ltd (ASX:CU6) is entering the most consequential stretch of its development story, with both pivotal Phase III trials for its lead imaging agent 64Cu-SAR-bisPSMA approaching results. AMPLIFY, which targets prostate cancer biochemical recurrence, closed recruitment in March with 232 participants dosed and imaged across the United States and Australia. CLARIFY, testing the agent before prostatectomy in high-risk patients, is still recruiting and is expected to complete in 2026.

The company intends to use the two trials to support potential US Food and Drug Administration applications in separate prostate cancer imaging settings. That remains an intended pathway, not an approval: the filing makes clear that Clarity is still pre-commercial and has generated no commercial product revenue.

Head-to-head data strengthens the diagnostic case

The strongest clinical evidence in the report comes from the 50-patient Co-PSMA investigator-initiated study, which compared 64Cu-SAR-bisPSMA directly with standard-of-care 68Ga-PSMA-11 in men with biochemical recurrence and low PSA levels. Next-day imaging identified 1.26 lesions per patient against 0.48 for the comparator, a 2.63-fold difference with a p-value below 0.0001. Positive scans were recorded in 78% of participants with Clarity’s agent, versus 36% with 68Ga-PSMA-11.

The reported management impact is potentially more important than the scan count: active planned treatment rose from 66% after 68Ga-PSMA-11 imaging to 90% after 64Cu-SAR-bisPSMA imaging. Still, Co-PSMA was a 50-patient study, while the company’s real-world evidence covered only ten patients who had negative or equivocal standard scans. Those results found lesions in eight patients, but the larger question is whether the Phase III datasets reproduce the advantage under registrational scrutiny.

Early therapy signals arrive alongside rising cash burn

Clarity’s therapeutic program is producing eye-catching, if preliminary, results. In the SECuRE trial, 19 participants treated at the 8 GBq 67Cu-SAR-bisPSMA dose level recorded PSA50 responses in 63% of cases and PSA90 responses in 26%; 81% of the 16 participants evaluable for radiographic assessment achieved disease control. Five in that subset had complete response or undetectable disease, contributing to seven such cases across the broader 67Cu-SAR-bisPSMA program.

The numbers come from a small, heavily pre-treated cohort, with a median of two treatment cycles and responses still maturing. The company reported mostly mild or moderate, transient treatment-related adverse events at 8 GBq, with no related Grade 4 or higher events in the assessed group. Further cohort-expansion data will be needed before the early response rate can be judged as more than a promising signal.

The financial statements show the cost of pursuing that opportunity. Clarity’s FY2026 net loss widened to AUD107.2 million from AUD64.3 million, while research and development expenditure rose to AUD91.1 million, largely reflecting higher clinical trial activity. Operating cash outflow reached AUD92.5 million, but the AUD203 million placement completed in July 2025 left the company with AUD178.3 million in cash and term deposits at 30 June 2026. The report says forecasts support at least 12 months of operations, while also acknowledging that additional capital may be required beyond the current forecast period.

Manufacturing network moves ahead of regulatory risk

Clarity is building its supply chain before it has a product approved. Agreements with Theragenics for copper-64, Nucleus RadioPharma for 64Cu-SAR-bisPSMA manufacturing and Nusano for copper-67 add capacity across the US, while existing arrangements with SpectronRx, NorthStar Medical Radioisotopes and Idaho State University’s Idaho Accelerator Center provide further supplier coverage. The company says its agreements could support more than two million 64Cu-SAR-bisPSMA patient doses a year at launch, although that capacity is not the same as demand or regulatory clearance.

The pipeline is broadening, too. Clarity is planning a registrational Phase III study for 64Cu-SARTATE in neuroendocrine tumours after positive FDA discussions, while SAR-bisFAP and SAR-HER2 remain preclinical or early development programs. The commercialisation team has expanded with senior appointments in regulatory affairs, commercial operations and technical operations, a useful preparation for launch but also a new source of expenditure before revenue begins.